Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).